Salma Jabbour, MD, on AEs Observed With Pembrolizumab Plus Concurrent Chemoradiotherapy in Stage III NSCLCFebruary 23rd 2021
The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed the adverse events associated with the use of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
Salma Jabbour, MD, on the Results of the Ongoing KEYNOTE-799 StudyFebruary 17th 2021
The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed updated results from the study of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
ACR Appropriateness Criteria® Borderline and Unresectable Pancreas CancerJuly 15th 2016
These guidelines review the use of radiation, chemotherapy, and surgery in borderline and unresectable pancreas cancer. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.
ACR Appropriateness Criteria® Resectable Stomach CancerAugust 15th 2015
For resectable gastric cancer, perioperative chemotherapy or adjuvant chemoradiation with chemotherapy are standards of care. The decision making for adjuvant therapeutic management can depend on the stage of the cancer, lymph node positivity, and extent of surgical resection.
ACR Appropriateness Criteria® Rectal Cancer: Metastatic Disease at PresentationOctober 15th 2014
The management of rectal cancer in patients with metastatic disease at presentation is highly variable. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial.